Ibrance (palbociclib) vs Truqap (capivasertib)
Ibrance (palbociclib) vs Truqap (capivasertib)
Ibrance (palbociclib) and Truqap (capivasertib) are both targeted therapies but they act on different pathways within cancer cells. Ibrance is a CDK4/6 inhibitor commonly used in combination with hormonal therapies to treat certain types of breast cancer, and its effectiveness is well-established in this setting. Truqap, on the other hand, is an AKT inhibitor that is being investigated for its potential in treating various cancers, including those resistant to other treatments; however, its use is not as widely approved or understood as Ibrance's. Patients should consult with their healthcare provider to determine the most appropriate treatment based on their specific type of cancer, its stage, and their overall health profile.
Difference between Ibrance and Truqap
| Metric | Ibrance (palbociclib) | Truqap (capivasertib) |
|---|---|---|
| Generic name | Palbociclib | Capivasertib |
| Indications | HR-positive, HER2-negative breast cancer | Advanced cancers with AKT pathway alterations (investigational) |
| Mechanism of action | CDK4/6 inhibitor | AKT inhibitor |
| Brand names | Ibrance | Truqap (not yet commercially available) |
| Administrative route | Oral | Oral (assumed, as it's in clinical trials) |
| Side effects | Neutropenia, infections, fatigue, nausea, alopecia | Hyperglycemia, rash, diarrhea, fatigue (based on clinical trials) |
| Contraindications | Known hypersensitivity to palbociclib or any of its excipients | Not yet fully established |
| Drug class | Antineoplastic agent | Investigational antineoplastic agent |
| Manufacturer | Pfizer | AstraZeneca (as of clinical trials) |
Efficacy
Ibrance (Palbociclib) and Its Efficacy in Breast Cancer
Ibrance (palbociclib) is a targeted therapy drug used to treat certain types of breast cancer. Specifically, it is approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Palbociclib works by inhibiting cyclin-dependent kinases (CDK) 4 and 6. These kinases are enzymes that promote cell division and are found in higher levels in cancer cells. By inhibiting these kinases, palbociclib can slow the progression of the cancer.
Clinical trials have demonstrated the efficacy of palbociclib in improving progression-free survival when used in combination with hormone therapy. For instance, the PALOMA-2 trial showed that first-line treatment with palbociclib in combination with letrozole significantly increased progression-free survival compared to letrozole alone in postmenopausal women with ER+/HER2- advanced breast cancer. The median progression-free survival was notably extended in the palbociclib group.
Truqap (Capivasertib) and Its Efficacy in Breast Cancer
Truqap (capivasertib) is an investigational drug that targets the AKT pathway, which is involved in cell growth and survival, and is often overactive in cancer cells. While capivasertib is not yet approved for clinical use, it has been studied in various phases of clinical trials for its potential to treat different forms of cancer, including breast cancer. Its efficacy in breast cancer is being evaluated in patients with advanced or metastatic disease, particularly those with alterations in the PIK3CA/AKT/PTEN pathway.
Initial results from clinical trials suggest that capivasertib, when used in combination with other therapies, may offer benefit to patients with breast cancer. For example, the FAKTION trial evaluated the addition of capivasertib to fulvestrant in patients with HR+/HER2- advanced breast cancer who had progressed on aromatase inhibitor therapy. The study found that the combination resulted in a statistically significant improvement in progression-free survival compared to the placebo group. Further studies are ongoing to confirm these findings and to determine the safety and efficacy of capivasertib in a larger cohort of patients.
Regulatory Agency Approvals
Ibrance
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Truqap
-
Food and Drug Administration (FDA), USA
Access Ibrance or Truqap today
If Ibrance or Truqap are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us